Of all today’s companies releasing financial updates, EP&T Global (ASX:EPX) was head and shoulders above the rest.


EP&T Global (ASX:EPX)

EP&T Global is a software stock which helps building owners and operators achieve savings from both cost and carbon footprint perspectives.

It only listed in May and has traded below its IPO price for a fair proportion of that time but today rose by over 50% after upgrading its Annualised Recurring Revenue (ARR) forecast.

At the end of FY21 the company’s ARR was $5.3 million but it is expecting this to be 85% higher – at $9.8 million – by the end of FY22.

The company reported a strong quarter with its EDGE Intelligence Systems being installed in 25 buildings.

EP&T Global (ASX:EPX) share price chart


Elmo Software (ASX:ELO)

This company is also a software stock but specialises in payroll and HR management.

It reported strong Annualised Recurring Revenue growth too, 61% greater than the prior corresponding period at $88.5 million.

Elmo said it was benefiting from the launch of new products as well as acquisitions including COVIDsecure which enables businesses to record, monitor and report their employees’ COVID vaccination and test status.

Elmo Software (ASX:ELO) share price chart


Healius (ASX:HLS)

It’s a good time to be in pathology.

In the past quarter Healius processed over 40,000 COVID-19 tests a day and it made $689.9 million in revenue as well as $201.9 million in underlying earnings.

Both are substantially higher than the $480.2 million in revenue and $77.9 million in earnings it made in FY20.

While the company’s day hospitals and imaging revenues were affected by lockdowns and restrictions on elective procedures, the company reported things were improving as restrictions were easing.

Healius (ASX:HLS) share price chart


Memphasys (ASX:MEM)

For medtechs yet to commercialise quarterlies are typically just a recap of the quarter that has been.

But for the sperm sorting device maker, the quarter was a positive one.

It finally put a long running legal battle behind it over its Felix device. It reached a settlement with its engineering and design partner over an engineering flaw that contributed to a substantial delay in sales.

Also, it expects a prototype device for use in horses to be field tested in the coming horse breeding season.

Memphasys (ASX:MEM) share price chart


Cimic (ASX:CIM)

Cimic is a construction contractor and it unveiled a profit for the last nine months of $303 million and $10.9 billion in group revenue.

So far this year it has been awarded $16 billion of new work and told shareholders it expects the ongoing government stimulus to continue to deliver work for the company.

Contracts it won during the quarter included a commercial complex for Equinox in India, the Warringah Freeway upgrade and a NZ$600m  maintenance contract for Auckland Rail.

Cimic (ASX:CIM) share price chart